NCT04936997View on ClinicalTrials.gov

Immune Response to the COVID-19 Vaccine

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 7, 2021

Primary Completion Date

August 25, 2021

Study Completion Date

May 8, 2022

Conditions
Covid19CancerMalignancyVaccine Response Impaired
Interventions
BIOLOGICAL

SARS-COV2 Pfizer Vaccine

Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Trial Locations (1)

85719

University of Arizona, Tucson

All Listed Sponsors
lead

University of Arizona

OTHER